Tobias Keßler

5.9k total citations
76 papers, 1.3k citations indexed

About

Tobias Keßler is a scholar working on Genetics, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Tobias Keßler has authored 76 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 40 papers in Genetics, 20 papers in Molecular Biology and 15 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Tobias Keßler's work include Glioma Diagnosis and Treatment (35 papers), Brain Metastases and Treatment (8 papers) and Radiomics and Machine Learning in Medical Imaging (8 papers). Tobias Keßler is often cited by papers focused on Glioma Diagnosis and Treatment (35 papers), Brain Metastases and Treatment (8 papers) and Radiomics and Machine Learning in Medical Imaging (8 papers). Tobias Keßler collaborates with scholars based in Germany, United States and Switzerland. Tobias Keßler's co-authors include Wolfgang Wick, Felix Sahm, Nicholas Guerina, Solomon Langermann, Donald A. Goldmann, Frank Winkler, Albrecht Hesse, Boris Jansen, Herbert W. Clegg and Thomas Vorherr and has published in prestigious journals such as Journal of Biological Chemistry, Nature Communications and The Journal of Experimental Medicine.

In The Last Decade

Tobias Keßler

71 papers receiving 1.2k citations

Peers

Tobias Keßler
Pamela Cohen United States
William M. Canfield United States
T. O'Reilly Switzerland
Theodore B. Moore United States
Pamela Cohen United States
Tobias Keßler
Citations per year, relative to Tobias Keßler Tobias Keßler (= 1×) peers Pamela Cohen

Countries citing papers authored by Tobias Keßler

Since Specialization
Citations

This map shows the geographic impact of Tobias Keßler's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Tobias Keßler with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Tobias Keßler more than expected).

Fields of papers citing papers by Tobias Keßler

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Tobias Keßler. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Tobias Keßler. The network helps show where Tobias Keßler may publish in the future.

Co-authorship network of co-authors of Tobias Keßler

This figure shows the co-authorship network connecting the top 25 collaborators of Tobias Keßler. A scholar is included among the top collaborators of Tobias Keßler based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Tobias Keßler. Tobias Keßler is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Warnken, Uwe, Dirk C. Hoffmann, Mirjam Korporal‐Kuhnke, et al.. (2025). Long-term CSF responses in adult patients with spinal muscular atrophy type 2 or 3 on treatment with nusinersen. Journal of Neurology. 272(4). 270–270. 2 indexed citations
2.
Burghaus, Ina, Tobias Keßler, Felix Sahm, et al.. (2024). PerSurge (NOA-30) phase II trial of perampanel treatment around surgery in patients with progressive glioblastoma. BMC Cancer. 24(1). 135–135. 26 indexed citations
3.
Wick, Wolfgang, Antje Wick, Inga Harting, et al.. (2024). CTNI-85. FINAL RESULTS FROM N2M2/NOA-20. Neuro-Oncology. 26(Supplement_8). viii117–viii117.
4.
Cho, Jae Young, Marianne Schell, Tobias Keßler, et al.. (2024). The potential of GPT-4 advanced data analysis for radiomics-based machine learning models. Neuro-Oncology Advances. 7(1). vdae230–vdae230. 1 indexed citations
5.
Schell, Marianne, Felix Sahm, Tobias Keßler, et al.. (2024). Advancing noninvasive glioma classification with diffusion radiomics: Exploring the impact of signal intensity normalization. Neuro-Oncology Advances. 6(1). vdae043–vdae043. 4 indexed citations
6.
Keßler, Tobias, Daniel Schrimpf, Leon D. Kaulen, et al.. (2023). Prognostic Markers of DNA Methylation and Next-Generation Sequencing in Progressive Glioblastoma from the EORTC-26101 Trial. Clinical Cancer Research. 29(19). 3892–3900. 11 indexed citations
8.
Keßler, Tobias, Philipp Eisele, Miriam Ratliff, et al.. (2023). Concurrent gliomas in patients with multiple sclerosis. SHILAP Revista de lepidopterología. 3(1). 186–186. 1 indexed citations
9.
Keßler, Tobias, et al.. (2023). Evaluation of risdiplam efficacy in 5q spinal muscular atrophy: A systematic comparison of electrophysiologic with clinical outcome measures. European Journal of Neurology. 31(1). e16099–e16099. 9 indexed citations
10.
Sammour, Denis Abu, Tobias Boskamp, Christian Marsching, et al.. (2023). Spatial probabilistic mapping of metabolite ensembles in mass spectrometry imaging. Nature Communications. 14(1). 1823–1823. 10 indexed citations
11.
Kaulen, Leon D., Christoph Gumbinger, Felix Hinz, et al.. (2022). Intraventricular immune checkpoint inhibition with nivolumab in relapsed primary central nervous system lymphoma. Neuro-Oncology Advances. 4(1). 8 indexed citations
12.
Wick, Antje, Anja Sander, Matthew J. Koch, et al.. (2022). Improvement of functional outcome for patients with newly diagnosed grade 2 or 3 gliomas with co-deletion of 1p/19q – IMPROVE CODEL: the NOA-18 trial. BMC Cancer. 22(1). 645–645. 6 indexed citations
13.
Jung, Erik, Matthias Osswald, Miriam Ratliff, et al.. (2021). Tumor cell plasticity, heterogeneity, and resistance in crucial microenvironmental niches in glioma. Nature Communications. 12(1). 1014–1014. 97 indexed citations
14.
Fletcher, Michael, Thomas Hielscher, Tobias Keßler, et al.. (2021). A novel patient stratification strategy to enhance the therapeutic efficacy of dasatinib in glioblastoma. Neuro-Oncology. 24(1). 39–51. 27 indexed citations
15.
Schell, Marianne, Gianluca Brugnara, Fabian Isensee, et al.. (2020). Validation of diffusion MRI phenotypes for predicting response to bevacizumab in recurrent glioblastoma: post-hoc analysis of the EORTC-26101 trial. Neuro-Oncology. 22(11). 1667–1676. 9 indexed citations
16.
Keßler, Tobias, Anne Berberich, Ahmed Sadik, et al.. (2020). Methylome analyses of three glioblastoma cohorts reveal chemotherapy sensitivity markers within DDR genes. Cancer Medicine. 9(22). 8373–8385. 14 indexed citations
17.
Berberich, Anne, Stefan Pusch, Thomas Hielscher, et al.. (2019). cMyc and ERK activity are associated with resistance to ALK inhibitory treatment in glioblastoma. Journal of Neuro-Oncology. 146(1). 9–23. 11 indexed citations
18.
Berberich, Anne, Tobias Keßler, Carina M. Thomé, et al.. (2018). Targeting Resistance against the MDM2 Inhibitor RG7388 in Glioblastoma Cells by the MEK Inhibitor Trametinib. Clinical Cancer Research. 25(1). 253–265. 50 indexed citations
19.
Wick, Wolfgang & Tobias Keßler. (2018). New glioblastoma heterogeneity atlas — a shared resource. Nature Reviews Neurology. 14(8). 453–454. 8 indexed citations
20.
Lohaus, Arnold & Tobias Keßler. (1996). Zum Zusammenhang zwischen Lösungsverhalten und verbalisiertem Verständnis des Lösungsprinzips bei der Wasserspiegelaufgabe. PUB – Publications at Bielefeld University (Bielefeld University). 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026